Naivek(36,400 +19.15%)Announced on the 17th that it has signed a substance transfer contract for gene drug delivery systems with global pharmaceutical companies and Biotech.
If this technology is commercialized, it is expected that it will be able to overcome the problem of cryogenic storage of ribonucleic acid (mRNA) vaccines. Naivek has been discussing technology transfer with global pharmaceutical companies such as introducing the gene drug delivery platform (NIPEP-TPP) technology at the JP Morgan healthcare conference last month.
The gene drug delivery platform is a technology that can accurately transfer gene drugs with large molecular sizes to the targeted lesion site without side effects, the company said.
In the course of discussions with global pharmaceutical companies, Naivec said that NIPEP-TPP delivered all data on the production and safety, as well as drug delivery and therapeutic effects. Among the mRNA Corona 19 vaccines, a vaccine using the lipid nanoparticle (LNP) method requires a facility to cool down to -80 degrees Celsius, and Naivek’s gene drug delivery technology has been evaluated as a means to overcome this.
A Naivek official said, “There is a high concern about safety, such as unwanted allergic reactions after administration of the Corona 19 vaccine based on lipid nanoparticles. These side effects are in areas other than those targeted by the vaccine administered to patients. This is because Naivek’s technology was delivered exactly to the target point, and the attention of pharmaceutical companies producing vaccines was focused.”
“The pharmaceutical company is reviewing the application of our technology to the field of gene therapy, including CAR-T, a rare disease, as well as vaccine treatment.” “The fact that Naivec has a cGMP-class synthetic facility was positively evaluated.” He added.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution